Viatris Stock Underperforms Nasdaq: Key Metrics Reveal Weakness
Viatris Inc. (VTRS), a prominent global pharmaceutical company with a market capitalization of $11.3 billion, continues to navigate a complex landscape within the specialty and generic drug manufacturing industry. Headquartered in Pennsylvania and operating in over 165 countries, Viatris boasts a diverse portfolio encompassing both generic and branded medicines, as well as biosimilars and active pharmaceutical ingredients (APIs). This broad range of offerings addresses key therapeutic areas, including cardiovascular health, oncology, central nervous system disorders, women’s health, and gastroenterology, demonstrating the company’s commitment to addressing significant unmet medical needs worldwide. Despite its substantial size and reach, Viatris’s stock performance has presented a mixed picture recently, reflecting broader market trends and specific company challenges. As of the article’s publication date, the stock price was notably 30% below its 52-week high of $13.55, achieved on November 25, 2024, indicating a period of underperformance compared to its recent peak.
The recent trajectory of Viatris stock contrasts with the performance of the Nasdaq Composite ($NASX), which has experienced a more robust upward trend. Over the past three months, Viatris shares have advanced by 6.8%, lagging considerably behind the Nasdaq’s 12.1% gain. This divergence highlights a specific weakness in Viatris’s stock relative to the overall market. Looking at a longer timeframe, Viatris’s performance has been persistently sluggish. The stock is down 23.8% year-to-date, meaning its value has decreased by 23.8% since the beginning of 2025. Furthermore, over the past 52 weeks, the stock has retreated by 15.8%, substantially underperforming the Nasdaq’s gains of 15.9% in 2025 and 23.8% over the past year. Technical indicators further reinforce a bearish outlook, as Viatris has maintained a position below its 200-day moving average since mid-January, and has recently dipped below its 50-day moving average. These moving averages are key technical benchmarks used to gauge the short-term and long-term trends of a stock, and their prolonged presence below Viatris’s price suggests a lack of sustained upward momentum.
Several factors appear to contribute to the company’s underperformance. On August 7th, Viatris released its fiscal 2025 second-quarter results, which triggered an initial 7.3% surge in the stock price. However, this rally proved to be short-lived, as the company reported revenues at $3.58 billion, a 6% decrease year-over-year on a reported basis and a 2% decrease on a divestiture-adjusted operational basis. While the company reported an adjusted earnings per share (EPS) of $0.62, a 10% decline, the adjusted EBITDA, or earnings before interest, taxes, depreciation, and amortization, experienced a slip of 11% to $1.08 billion. These results indicate pressure on the company’s core business operations and potentially reflect broader challenges in the pharmaceutical market. It’s important to consider that the figures represent a reported basis, which can be influenced by accounting practices and may not fully capture the underlying operational performance. The divestiture-adjusted operational basis attempts to isolate the core business performance, yet still relies on specific adjustments.
Notably, Viatris’s struggles have been exacerbated by the relative strength of its peer, Sanofi (SNY). Sanofi’s stock has declined by 5.8% in 2025 and a 20.3% decline over the past 52 weeks, demonstrating that Viatris’s underperformance isn’t solely a company-specific issue. The market’s perception of Sanofi might be influenced by factors such as broader industry trends, regulatory changes, or specific product performance that are not directly reflected in Viatris’s results. Analyzing the performance of comparable companies provides valuable context for assessing the viability of Viatris’s strategy. Currently, among the eight analysts covering the VTRS stock, the consensus rating is a “Hold.” This signifies that analysts believe the stock’s prospects are uncertain and do not recommend a buy or sell decision. The mean price target of $11.46 suggests a potential upside of 20.8% to current price levels, yet this projection is subject to numerous variables.
Information presented in this article is provided solely for informational purposes and should not be considered financial advice. Kritika Sarmah did not hold any direct or indirect positions in any of the securities mentioned.
